LUIS HENRIQUE WOLFF GOWDAK
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/13 - Laboratório de Genética e Cardiologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/13 - Laboratório de Genética e Cardiologia Molecular, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Trimetazidine in cardiovascular medicine (vol 293, pg 39, 2019)(2020) MARZILLI, Mario; VINEREANU, Dragos; LOPASCHUK, Gary; CHEN, Yundai; DALAL, Jamshed J.; DANCHIN, Nicolas; ETRIBY, El; FERRARI, Roberto; GOWDAK, Luis Henrique; LOPATIN, Yuri; MILICIC, Davor; PARKHOMENKO, Alexander; PINTO, Fausto; PONIKOWSKI, Piotr; SEFEROVIC, Petar; ROSANO, Giuseppe M. C.
- Trimetazidine in cardiovascular medicine(2019) MARZILLI, Mario; VINEREANU, Dragos; LOPASCHUK, Gary; CHEN, Yundai; DALAL, Jamshed J.; DANCHIN, Nicolas; ETRIBY, El; FERRARI, Roberto; GOWDAK, Luis Henrique; LOPATIN, Yuri; MILICIC, Davor; PARKHOMENKO, Alexander; PINTO, Fausto; PONIKOWSKI, Piotr; SEFEROVIC, Petar; ROSANO, Giuseppe M. C.Abnormalities of myocardial energy metabolism appear as a common background of the two major cardiac disorders: ischemic heart disease (IHD) and heart failure (HF). Myocardial ischemia has been recently conceived as a multifaceted syndrome that can be precipitated by a number of mechanisms including metabolic abnormalities. HF is a progressive disorder characterised by a complex interaction of haemodynamic, neurohormonal and metabolic disturbances. HF may further promote metabolic changes, generating a vicious cycle. Thus, targeting cardiac metabolism in IHD patients may prevent the deterioration of left ventricular function, stopping the progression to HF. For these reasons, several studies have explored the potential benefits of trimetazidine (TMZ), an inhibitor of free fatty acids oxidation that shifts cardiac and muscle metabolism to glucose utilization. Because of its mechanism of action, TMZ has been found to provide a cardioprotective effect in patients with angina, diabetes mellitus, and left ventricular (LV) dysfunction, and those undergoing revascularization procedures, without relevant side effects. In addition, the lack of interference with heart rate, arterial pressure, and most of frequent comorbidities, makes TMZ an attractive option for patients and clinicians as well. The impact of TMZ on long term mortality and morbidity in ischemic syndromes and in heart failure need to be conclusively confirmed in properly designed RCT. (C) 2019 Published by Elsevier B.V.
- Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure(2016) LOPATIN, Yuri M.; ROSANO, Giuseppe M. C.; FRAGASSO, Gabriele; LOPASCHUK, Gary D.; SEFEROVIC, Petar M.; GOWDAK, Luis Henrique W.; VINEREANU, Dragos; HAMIDI, Magdy Abdel; JOURDAIN, Patrick; PONIKOWSKI, PiotrHeart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.